01-03-2019
peshkova / Shutterstock.com
The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate (SPC).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Genentech, Eli Lilly, English High Court, marketing authorisation, supplementary protection certificate, SPC, psoriasis, rheumatoid arthritis, Brexit
UK govt’s £20m fund for life sciences opens for applications
08-04-2021
Genentech to face revived Hemlibra claims
28-08-2020
Eli Lilly claims another victory in Taltz patent battle
18-02-2020
Former Genentech employee cuts plea deal with FBI in trade secrets case
16-01-2020
CJEU opinion on SPC referral is ‘overdue’, say lawyers
05-03-2019
